TENX INVESTOR ALERT: Class Action Lawsuit Filed on Behalf of Tenax Therapeutics, Inc. Investors – Holzer & Holzer, LLC Encourages Investors With Losses to Contact the Firm

Impact · against what's priced in

Tenax Therapeutics faces a potential valuation reset due to a shareholder class action lawsuit alleging that the company overstated the efficacy and commercial viability of its lead asset, TNX-103. The news introduces significant litigation risk and casts doubt on the drug's clinical prospects.

TENX−0.60

No priced-in read yet